Patients in the nonsomnolent/nonsedating subgroup who were on duloxetine showed improvements in daily average pain and night pain
severity, compared with those on placebo.
Five patients complained of occasional night pain
at the time of their last follow-up examination.
001 versus placebo) were confirmed by secondary outcome measures as well, including night pain
scores, Clinical Global Impressions for pain severity, and the SF-36 Health Status Survey sections addressing mental health and general health perceptions.
Improvement was also statistically significant for VAS night pain
, Jamar hand-grip strength, total number of Fibromyalgia tender points and the average tender point pain threshold as measured by algometry.
INDIANAPOLIS, May 3 /PRNewswire-FirstCall/ -- Data from a pooled analysis of three studies suggest that in patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta (duloxetine HCl), improvements in both average daily pain and night pain
severity were associated with less pain-related sleep interference than in those patients taking sugar pill.
Patients receiving REMICADE also showed significant improvements in individual measurements of disease activity, function, and mobility, as well as improvements in chest expansion, reduction in night pain
and patient global assessment.